Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single-Arm, Open-Label, Extension, Rollover Study To Evaluate The Long-Term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis

NCT05269004 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05269004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05269004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single-Arm, Open-Label, Extension, Rollover Study To Evaluate The Long-Term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 3, 2022
Completion date
December 31, 2027
Enrollment
1,300 (estimated)
Sites
236

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis